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Abstract
Background: Pandemic influenza A(H1N1) 2009 began spreading around the globe in April of 2009 and vaccination started
in October of 2009. In most countries, by the time vaccination started, the second wave of pandemic H1N1 2009 was
already under way. With limited supplies of vaccine, we are left to question whether it may be a good strategy to vaccinate
the high-transmission groups earlier in the epidemic, but it might be a better use of resources to protect instead the high-
risk groups later in the epidemic. To answer this question, we develop a deterministic epidemic model with two age-groups
(children and adults) and further subdivide each age group in low and high risk.
Methods and Findings: We compare optimal vaccination strategies started at various points in time in two different
settings: a population in a developed country where children account for 24% of the population, and a population in a less
developed country where children make up the majority of the population, 55%. For each of these populations, we
minimize mortality or hospitalizations and we find an optimal vaccination strategy that gives the best vaccine allocation
given a starting vaccination time and vaccine coverage level. We find that population structure is an important factor in
determining the optimal vaccine distribution. Moreover, the optimal policy is dynamic as there is a switch in the optimal
vaccination strategy at some time point just before the peak of the epidemic. For instance, with 25% vaccine coverage, it is
better to protect the high-transmission groups before this point, but it is optimal to protect the most vulnerable groups
afterward.
Conclusions: Choosing the optimal strategy before or early in the epidemic makes an important difference in minimizing
the number of influenza infections, and consequently the number of influenza deaths or hospitalizations, but the optimal
strategy makes little difference after the peak.
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Introduction
For the pandemic H1N1 2009 influenza, vaccine production
started in the early summer of 2009. Several countries immediately
ordered vaccine [1,2], with the hope that the first production
batches would be ready in the early fall of 2009. This was not the
case, however, and for most countries vaccine arrived much later
than predicted. Meanwhile, the World Health Organization
(WHO) expected to supply 95 low-and middle-income countries
with enough vaccine to cover 10% of their populations [3]. When
vaccine supplies are limited, vaccinating the high-transmission
groups, such as school children or young adults, has proven to be a
good strategy for preventing the spread of the disease, and by
doing so the groups at high risk will be indirectly protected
[4,5,6,7]. While this strategy makes sense earlier in the epidemic,
this might not be the optimal use of vaccine once the epidemic has
begun. Indeed, once there is a large proportion of the high-
transmission groups infected and later on immune, vaccine would
probably have little effect in these groups and could be more
effectively used in the high-risk groups, giving them direct
protection. When and who should receive vaccine first is still an
open question. Recent advances have been made in this direction
[8,9,10,11,12], but the problem is complex and depends on
multiple factors. For instance, the optimal use of vaccines depends
on the population structure: countries or cities where school
children or college students make up large proportions of the
population will have different epidemic dynamics than a country
where these younger people make up a smaller proportion of
the population. Therefore, different countries with different
socioeconomic backgrounds will have different epidemic dynam-
ics, and should consequently optimize their resources according
to their needs.
In the present work, we developed a deterministic model with
two groups, children and adults, and we further divided each of
these age groups into low and high risk. We compared optimal
vaccination strategies in two different settings: 1. A population in a
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13767developed country (in what follows denoted by DC), where the
children make up 24% of the population [13], and 2. a population
in a less developed country (in what follows denoted by LDC),
where the children account for 55% of the population [14].
Examples of countries with the former population structure would
be countries like the United States, France, United Kingdom or
Australia, while examples of countries with the latter structure
would include Senegal, Cameroon, and Bolivia [14]. For each of
these populations, we minimize mortality or hospitalizations, and
we find an optimal vaccination strategy that gives us the best




Our model for influenza is based on the SIR model (see Text S1
for the detailed model). We considered a closed population of size
N. Since influenza has a very short time scale compared to
immigration or demographics, none of these features are included.
We divided the population into two sub-populations of children
and adults of size N1 and N2, so that N~N1zN2. Furthermore,
within each sub-population, we divide members into high risk and
low risk. Members in each group are either susceptible, infected
asymptomatic, infected symptomatic or recovered and immune. In
addition, people can be either vaccinated or unvaccinated. The
following assumptions were made.
N A fraction r of the infected people will never develop
symptoms but will still transmit the infection to others.
Asymptomatic infected people have their infectiousness
reduced by a factor m compared to symptomatic infected
people, where m[ 0,1 ½  .
N Let cij be the number of contacts per day between people in
age group i and people in age group j, where i,j~1,2.W e
assumed cij~cji.
N p is the probability of infection given contact.
N People are infectious as soon as they get infected, and they will
stay infectious for an average of 1=c time units, where c is the
recovery rate.
N Following the ideas in [15], vaccination has three major effects:
(i) VES, the vaccine efficacy for susceptibility, which is the
ability of the vaccine to prevent infection.
(ii) VEI, the vaccine efficacy for infectiousness, which is the
effect of the vaccine in reducing infectiousness and
transmission to others.
(iii) VEP, the vaccine efficacy for pathogenicity, which accounts
for the effect of the vaccine in reducing the symptoms given
infection.
N The effect of each of the efficacies builds monotonically in time
according to expontial-like functions. Based on previous
immunogenicity studies (e.g., [16,17,18,19]), we assumed that
the vaccine efficacy will reach its full potential 14 days after
being administered. In addition, we assumed that the vaccine
efficacies do not wane over the time period being modeled.
A detailed description of the model can be found in Text S1.
Model calibration
We used the United States (US) as a basis for the developed
country setting. We then calibrated this model for the pandemic
H1N1 2009 in the US according to the numbers given in table S2
to obtain the final illness attack rates (defined as the percentage of
the population that became ill) shown in table S3. For the less
developed country setting, the parameters were taken to be all
identical to those from the US except for the proportion of
children in the population, the influenza-related mortality, and the
influenza-related hospitalizations. Since this kind of data is rarely
collected and difficult to obtain for less developed countries, we
assumed two extreme scenarios. First, we assumed that both the
rates of influenza-related mortality and hospitalizations for each
Figure 1. Epidemic curves for both the less developed country (LDC) and the developed country (DC). Caption: Epidemic curves for all
the basic reproduction numbers considered and for both the less developed country (LDC) and the developed country (DC) in absence of
vaccination. The circles in black denote the starting vaccination times considered for each given R0.
doi:10.1371/journal.pone.0013767.g001
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ones in the US. Then, we used infant mortality rate in less
developed countries as a proxy for the excess of influenza-related
mortality and hospitalizations in children in less developed
countries. The infant mortality rate was computed as an average
of five less developed countries among the ones receiving vaccine
from WHO, based on the numbers given in [14]. That is, we
computed the ratio of the average infant mortality rate in less
developed countries and the infant mortality rate in the US and
adjusted the influenza-related mortality rate and the hospitaliza-
tion rate in less developed countries by multiplying them by this
factor. Similarly, based on [20] we used excess in female adult
mortality as a proxy for the influenza-related mortality and
hospitalizations in the adult group. Here, we used hospitalizations
in a LDC as a proxy for severity. The number of hospitalizations
represents the number of severe cases that would require medical
attention, but not necessarily the number of cases that will go to
the hospital. This is because in a LDC, the health seeking behavior
and hospital capacity might be extremely different from the DC
setting, and extrapolation might not be adequate.
Implementing vaccination
Based on current estimates [21,22,23], we considered the basic
reproduction number R0 to be in the set f1:4,1:6,1:8g. The basic
reproduction numbers were computed following the approach
given in [24] and [25,26]. We investigated the influence of the
timing of the vaccination program on its effect. To do this, we
considered, for each basic reproduction number, six different times
for starting vaccination: two of them before the exponential phase
of the epidemic, two of them during the exponential phase of the
epidemic, one close the peak of the epidemic curve, and one
further after the peak (figure 1 and table S1).
The World Health Organization (WHO) has pledged to give
enough vaccine to less developed countries to cover 10% of their
Figure 2. Optimal vaccination policy for a developed country. Caption: Optimal vaccination policy when there is enough vaccine to cover
(A) 2%, (B) 15%, or (C) 25% of the population in a developed country starting one, 20, 40, 60, 80, or 90 days after the beginning of transmission. The
epidemic curve for the symptomatic infections (without any intervention) is shown in black. The left panel minimizes the number of hospitalizations,
while the right panel minimizes the number of deaths.
doi:10.1371/journal.pone.0013767.g002
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DC Day 1 Day 20 Day 40 Day 60 Day 80 Day 90
2% coverage Optimal strategy (hospitalizations) [0 93 0 0]
a [0 93 0 0] [0 93 0 0] [0 93 0 0] [0 93 0 0] [0 93 0 0]
Illness Attack Rate (%) 24.6 24.6 24.7 25.8 27.2 27.5
Hospitalizations (per 100 cases) 0.3896 0.3898 0.3929 0.4203 0.4485 0.4523
Optimal strategy (deaths) [0 93 0 0] [0 93 0 0] [0 93 0 0] [0 93 0 0] [0 93 0 0] [0 93 0 0]
Illness Attack Rate (%) 24.6 24.6 24.7 25.8 27.2 27.5
Deaths (per 1000 cases) 0.1723 0.1723 0.1726 0.1757 0.1790 0.1795
15% coverage Optimal strategy (hospitalizations) [58 100 0 0] [58 100 0 0] [58 100 0 0] [58 100 0 0] [0 100 0 80] [0 100 0 80]
Illness Attack Rate (%) 0.019 0.3 3.8 16.5 26.5 27.2
Hospitalizations (per 100 cases) 0.4234 0.4237 0.4277 0.4433 0.4370 0.4478
Optimal strategy (deaths) [58 100 0 0] [58 100 0 0] [58 100 0 0] [58 100 0 0] [0 98 0 80] [0 0 0 93]
Illness Attack Rate (%) 0.019 0.3 3.8 16.5 26.5 27.2
Deaths (per 1000 cases) 0.1968 0.1948 0.1924 0.1843 0.1698 0.1753
25% coverage Optimal strategy (hospitalizations) [100 100 0 5] [100 100 0 5] [100 100 0 5] [100 100 0 5] [30 100 0 100] [30 100 0 100]
Illness Attack Rate (%) 0.005 0.08 1.5 13.3 25.6 26.8
Hospitalizations (per 100 cases) 0.4534 0.4528 0.4528 0.4532 0.4395 0.4487
Optimal strategy (deaths) [100 100 0 5] [100 100 0 5] [100 100 0 5] [30 100 0 100] [30 100 0 100] [30 100 0 100]
Illness Attack Rate (%) 0.005 0.08 1.5 17.7 25.6 26.8
Deaths (per 1000 cases) 0.2006 0.1934 0.1920 0.1366 0.1702 0.1759
a[0 93 0 0] denotes the percentages of people vaccinated in each class, where the first entry corresponds to children low-risk, the second one to children high-risk, the
third one to adults low-risk and finally adults high-risk.
doi:10.1371/journal.pone.0013767.t001
Figure 3. Epidemic curves for a developed country and for a less developed country at two different times. Caption: Epidemic curves
for a developed country (DC) and for a less developed country (LDC) with vaccination starting at two different times: on day 20 (left panel) and on day
65 (right panel) if we had enough vaccine to cover 15% of the population. The dotted lines represent the baseline epidemic curves for a DC and LDC
with no intervention. The dashed lines represent the epidemic curve where we vaccinated all the high-risk children (100%) and used the remainder
vaccine in low-risk children (40% in LDC and 58% in DC), while the solid lines represent the epidemic curve corresponding to vaccinate all high-risk
children (100%) and high-risk adults (100% in LDC and 80% in DC). For day 20, the optimal vector f
 , favoring children, (f
 ~(58,100,0,0) for a DC and
f
 ~(40,100,0,0) for a LDC) mitigates the epidemic while the other strategy only reduces it. By day 65, both strategies perform poorly.
doi:10.1371/journal.pone.0013767.g003
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was delivered in batches. In the US, the first batch of vaccine was
assumed to be enough for 20% of the population [28]. With this in
mind, we considered vaccine supplies with enough to cover 2%,
15% or 25% of the population.
For simplicity, we assumed for a given coverage that all the
vaccine is delivered at once, however, vaccinated people acquire
their protection gradually as the vaccine efficacies build up over
time (figure S1). For further details, the kinetics of the vaccine
effects are given in Text S1.
Optimization
Define a vaccination control vector f~(fl1,fh1,fl2,fh2). For each
possible vector f, fl1 and fh1 are the fractions of vaccinated
children at low and high risk, respectively, and fl2 and fh2 are the
fractions of vaccinated adults at low and high risk, respectively.
Using a line search optimization algorithm in MATLAB, we
determined the vector f
  that would give us the optimal vaccine
distribution for minimizing either the total number of deaths or
the total number of hospitalizations for each of the vaccination
initialization times and vaccine coverages given above. Thus, the
vector f




h2) gives us the fractions f  
l1 and f  
h1 of
children at low and high risk, and the fractions f  
l2 and f  
h2 of adults
at low and high risk respectively that would minimize total
mortality or total hospitalizations during the entire epidemic.
Further details are given in Text S1.
Results
For this analysis, we will focus on a basic reproduction number
of 1.6. The results for R0~1:4 and R0~1:8 are summarized in
tables S4, S5, S6, S7, S8, S9.
Results for a developed country (DC)
The baseline epidemic curves for both a DC and a LDC for
R0~1:6 are plotted in red in figure 1. Both countries have similar
Figure 4. Optimal vaccination policy for a less developed country, unadjusted. Caption: Optimal vaccination policy when there is enough
vaccine to cover (A) 2%, (B) 15%, or (C) 25% of the population in a less developed country starting one, 20, 40, 60, 80, or 90 days after the beginning
of transmission. The epidemic curve for the symptomatic infections (without any intervention) is shown in black. Here, the rates for influenza-related
mortality and hospitalizations in a less developed country are exactly the same as those in a developed country (see text S1). The left panel minimizes
the number of hospitalizations, while the right panel minimizes the number of deaths.
doi:10.1371/journal.pone.0013767.g004
Optimizing Vaccine Allocation
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e13767epidemic curves in that there is no substantial spread before day
60, and the exponential phase of the epidemic starts around day
45. The peak for the LDC occurs slightly earlier than for the DC.
Figure 2 and table 1 summarize the results for the DC
population. For each vaccination coverage (figure 2A–2C), the
figure shows the optimal vaccine allocation if vaccination were to
start one, 20, 40, 60, 80, or 90 days after the beginning of
transmission, both for minimizing hospitalizations (left panel) and
mortality (right panel). When there is enough vaccine to cover only
two percent of the DC population, the best strategy in both cases is
to allocate all the vaccine to the high-risk children (93% coverage)
regardless of when vaccination begins (see figure 2).
When supplies are large enough to vaccinate 15% of the
population (figure 2B), the optimal strategy to reduce both
hospitalizations and mortality is to vaccinate all of the high-risk
children and then to concentrate the remainder of the vaccine in
low-risk children, provided that vaccination occurs before the
peak. However, after the peak, it is optimal to cover all high-risk
children and to give the remaining vaccine to high-risk adults (this
accounts for 80% coverage in this group). For instance, if
vaccination were to start 20 days after the beginning of
transmission, it would be optimal to give vaccine to all the
children at high risk (100% coverage in this group) and to allocate
the rest to the children at low risk (58% coverage in this group),
but if vaccination were to start 80 days after the beginning of
transmission, then it would be optimal to still vaccinate all the
high-risk children but to vaccinate a fraction of the high-risk adults
(80% coverage in this group). By day 90, it is better to allocate all
resources to high-risk adults if minimizing mortality. However, it is
important to note that once that the peak of the epidemic has
occurred, vaccination has a minimal effect and both strategies
mentioned above perform equally poorly (figure 3).
Figure 2C presents the results for the DC when enough vaccine
is available to cover 25% of the population. Assuming that
vaccination occurred before the exponential phase of the
epidemic, vaccinating all of the high-risk children and then
concentrating the remainder of the vaccine in low-risk children
(90% coverage in this group) is the optimal solution, but this time a
small amount of vaccine can be given to high-risk adults (19%
coverage in high risk adults). In contrast, if vaccination takes place
during or after the exponential phase, then it is optimal to favor
first all of the high-risk children and all high-risk adults, and then
to concentrate the remainder of supplies in low-risk children (30%
coverage in low-risk children). For this coverage, the switch in the
optimal allocation occurs earlier on if minimizing mortality: By
day 80, is better to vaccinate all high-risk people and use the
remainder in low-risk children (30% coverage of this group) rather
than completely protecting all children and allocate the remainder
for high-risk adults.
Results for a less developed country (LDC)
Mortality and hospitalizations unadjusted. Figure 4 and
table 2 show the analogous results for a LDC, where the
hospitalizations and mortality rates were considered to be equal
to those in a DC. In this scenario, children make up a much larger
proportion of the population (55%) than they do in the DC (24%).
When minimizing hospitalizations for very low coverage (2% of
the population), it is always optimal to allocate all of the vaccine to
high-risk children. However, when minimizing mortality and
when vaccination were to occur before the exponential phase, it is
optimal to concentrate all of the available vaccine in high-risk
children (41% coverage); whereas if vaccination were to occur
during or after the exponential phase, it is optimal to shift vaccine
coverage to high-risk adults (21% coverage), see figure 4A.
When there is enough vaccine for 15% of the population, the
results are quite different for minimizing mortality or hospitaliza-
tions. For the former, regardless of the phase of the epidemic, it is
optimal to protect both the high-risk groups, children and adults,
and to allocate the remainder of supplies in low-risk children (1%
coverage in this group) before the peak, or low risk adults after the
Table 2. Results for a Less Developed Country (LDC), influenza-related mortality and hospitalizations unadjusted, R0 =1.6.
LDC (unadjusted) Day 1 Day 20 Day 40 Day 60 Day 80 Day 90
2% coverage Optimal strategy (hospitalizations) [0 41 0 0] [0 41 0 0] [0 41 0 0] [0 41 0 0] [0 41 0 0] [0 41 0 0]
Illness Attack Rate (%) 32.7 32.7 32.8 34 34.4 34.5
Hospitalizations (per 100 cases) 0.3979 0.3981 0.4004 0.4213 0.4438 0.4470
Optimal strategy (deaths) [0 41 0 0] [0 41 0 0] [0 41 0 0] [0 0 0 21] [0 0 0 21] [0 0 0 21]
Illness Attack Rate (%) 32.7 32.7 32.8 34 34.4 34.5
Deaths (per 1000 cases) 0.1127 0.1127 0.1130 0.1139 0.1180 0.1189
15% coverage Optimal strategy (hospitalizations) [20 100 0 0] [20 100 0 0] [20 100 0 0] [1 100 0 100] [1 100 0 100] [1 100 0 100]
Illness Attack Rate (%) 19.3 19.5 20.4 29.4 33.4 34.2
Hospitalizations (per 100 cases) 0.3290 0.3296 0.3380 0.3529 0.4313 0.4460
Optimal strategy (deaths) [1 100 0 100] [1 100 0 100] [1 100 0 100] [1 100 0 100] [0 100 2 100] [0 100 2 100]
Illness Attack Rate (%) 26.1 26.1 26.4 29.4 33.4 34.2
Deaths (per 1000 cases) 0.0599 0.0600 0.0625 0.0851 0.1119 0.1165
25% coverage Optimal strategy (hospitalizations) [40 100 0 0] [40 100 0 0] [40 100 0 0] [21 100 0 100] [21 100 0 100] [21 100 0 100]
Illness Attack Rate (%) 1.25 5.3 10.2 24.7 32.6 33.8
Hospitalizations (per 100 cases) 0.3378 0.3422 0.3581 0.3706 0.4354 0.4438
Optimal strategy (deaths) [40 100 0 0] [40 100 0 0] [40 100 0 0] [21 100 0 100] [14 100 10 100] [0 100 30 100]
Illness Attack Rate (%) 1.25 5.3 10.21 24.72 32.7 33.9
Deaths (per 1000 cases) 0.1141 0.1169 0.1187 0.0905 0.1129 0.1166
doi:10.1371/journal.pone.0013767.t002
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not be able to block transmission by protecting the high-
transmission groups. So it is better to directly protect all the
members of the most vulnerable groups, and by doing so the
number of deaths are greatly diminish. For minimizing hospital-
izations, vaccinating low-risk children earlier in the epidemic
instead of high-risk adults is better, but later on protecting the
high-risk groups is optimal (figure 4B).
With enough vaccine to protect 25% of the population, the
optimal solutions for minimizing mortality and hospitalizations are
identical if vaccination were to occur before the peak of the
epidemic. In this case, it is optimal to concentrate vaccine in
children (100% of the high-risk children and 40% of the low-risk),
see figure 4C. But when vaccination occurs later on, the optimal
strategy shifts to the high-risk groups, (100% coverage of both
children and adults at high-risk) with allocation of the re-
mainder of the vaccine to low-risk children (21% coverage in this
group) to minimize hospitalizations, or to low-risk adults when
minimizing mortality.
Adjusted mortality and hospitalizations. Figure 5 and
table 3 summarize the results for a LDC where we adjusted for the
excess in mortality and hospitalizations. This leads to more
uniform policies in which children tend to get vaccinated. For low
coverage, the optimal policy is always, for all times considered, to
cover the high-risk children (see figure 5A). As coverage increases,
it is optimal to first protect high-risk children, secondly, to allocate
the remainder of the resources either to low-risk children or to
high-risk adults and then to allocate any extra vaccine to low-risk
children. The former is optimal before the exponential phase of
the epidemic, while the latter is better if vaccination starts later on
(see figure 5B). Minimizing the number of deaths tends to move
the threshold for protecting high-risk adults over low-risk children
to the left. For example, when there is enough vaccine to cover
25% of the population, it is optimal to cover high-risk adults over
Figure 5. Optimal vaccination policy for a less developed country, adjusted. Caption: Optimal vaccination policy when there is enough
vaccine to cover (A) 2%, (B) 15%, or (C) 25% of the population in a less developed country starting one, 20, 40, 60, 80, or 90 days after the beginning
of transmission. The epidemic curve for the symptomatic infections (without any intervention) is shown in black. Here, the model was adjusted to
account for the excess in mortality and hospitalizations in a less developed country compared with a developed country (see text S1). The left panel
minimizes the number of hospitalizations, while the right panel minimizes the number of deaths.
doi:10.1371/journal.pone.0013767.g005
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wanted to avert deaths. However the opposite would hold if we
wanted to avert hospitalizations (figure 5C).
Sensitivity analysis
Choosing the optimal strategy is extremely important before the
peak of the epidemic, but once we reach it, vaccination has little
effect and all strategies perform poorly. Figure 3 shows the
epidemic curves for a DC and for a LDC with vaccination starting
at two different times: On day 20 (left panel) and on day 65 (right
panel) if we had enough vaccine to cover 15% of the population in
each country. In each panel, we plotted two strategies: the optimal
strategy for day 20 (this is, vaccinating 40% of the low-risk children
and 100% of the high-risk children) and the optimal strategy for
day 65 (this corresponds to vaccinating 21% of the low-risk
children, and fully protect the high-risk groups). Choosing the
optimal strategy if vaccination starts on day 20 mitigates the
epidemic for the DC, and gives a very mild epidemic in the LDC,
while vaccinating the high-risk people only reduces the size of the
epidemic in both countries. However, by day 65, both policies give
similar epidemic curves that almost overlay with the baseline
curve.
If vaccination occurs early in the epidemic or the coverage is
very low (2%), then the optimal vaccine allocation is not sensitive
to changes in the basic reproduction number R0. However, when
vaccine coverage increases, then the optimal strategy to minimize
deaths, and to a lesser extent, to minimize hospitalizations, shifts
from low-risk children to high-risk adults faster as R0 increases (see
figure S2).
The model is very sensitive to the parameters for excess of
deaths and hospitalizations in less developed countries. In order to
investigate this, we repeated the analysis and halved the values of
each of these parameters i.e., the influenza-related mortality and
hospitalizations were increased by a factor of four instead of a
factor of eight in children and by 1.5 instead of three in adults.
Figure 6 shows the percentage of the total number of doses used in
each group when there is enough vaccine to protect 15% of the
population and the optimization was set to minimize mortality.
When mortality and hospitalizations are not adjusted, the model
favors the high-risk groups, especially early on in the epidemic. As
we increase the multipliers adjusting for these parameters, the
optimal solution shifts to favor the low-risk children instead.
Varying the proportions of high-risk people, the mortality and the
hospitalization rates in each group greatly changes the optimiza-
tion policies. This is expected as these numbers determine the
outcome of the optimization directly. Augmenting these param-
eters in a given group will result in an optimal strategy where that
group tends to be favored (see Text S1 and figures S3 and S4).
Discussion
We use a mathematical model to find the optimal vaccine
allocation at different time points of an epidemic. For both
developed and less developed countries, when faced with low
supplies of vaccines, it is always optimal to concentrate vaccine in
high-risk children to provide them with direct protection, as they
are part of the high-transmission chain and they are among the
most vulnerable.
Fora developedcountry,asvaccine suppliesincreases, itbecomes
optimal to allocatetheresourcesinthe high-transmission group, i.e.,
children at low-risk. This makes sense, since by protecting the high-
transmission group, we stop the chain of transmission and indirectly
protect the high risk groups. However, this policy is optimal only up
to a certain time during or after the exponential rise phase of the
epidemic, when too many high-transmission people have already
been infected and have acquired natural immunity. After this point
in time, it is optimal to concentrate vaccine in high-risk groups
protecting them directly. Minimizing mortality, as opposed to
hospitalizations, tends to push this threshold to the left in time so
that the protection of high-risk adults starts earlier.
Table 3. Results for a Less Developed Country (LDC), influenza-related mortality and hospitalizations adjusted, R0 =1.6.
LDC (adjusted) Day 1 Day 20 Day 40 Day 60 Day 80 Day 90
2% coverage Optimal strategy (hospitalizations) [0 41 0 0] [0 41 0 0] [0 41 0 0] [0 41 0 0] [0 41 0 0] [0 41 0 0]
Illness Attack Rate (%) 32.7 32.8 32.8 33.5 34.4 34.5
Hospitalizations (per 100 cases) 2.5093 2.5103 2.5293 2.7016 2.8858 2.9119
Optimal strategy (deaths) [0 41 0 0] [0 41 0 0] [0 41 0 0] [0 41 0 0] [0 41 0 0] [0 41 0 0]
Illness Attack Rate (%) 32.7 32.8 32.8 33.5 34.4 34.5
Deaths (per 1000 cases) 0.5308 0.5310 0.5337 0.5584 0.5849 0.5886
15% coverage Optimal strategy (hospitalizations) [20 100 0 0] [20 100 0 0] [20 100 0 0] [20 100 0 0] [10 100 0 55] [10 100 0 55]
Illness Attack Rate (%) 19.3 19.5 20.4 26.8 33.3 34.1
Hospitalizations (per 100 cases) 1.8765 1.8804 1.9545 2.4732 2.8463 2.8956
Optimal strategy (deaths) [20 100 0 0] [20 100 0 0] [1 100 0 100] [1 100 0 100] [1 100 0 100] [1 100 0 100]
Illness Attack Rate (%) 19.3 19.5 26.4 29.4 33.4 34.4
Deaths (per 1000 cases) 0.4568 0.4568 0.3356 0.4463 0.5627 0.5801
25% coverage Optimal strategy (hospitalizations) [40 100 0 0] [40 100 0 0] [40 100 0 0] [40 100 0 0] [21 100 0 100] [21 100 0 100]
Illness Attack Rate (%) 1.25 5.3 10.2 22.6 32.6 33.8
Hospitalizations (per 100 cases) 1.8984 1.9066 2.0416 2.5836 2.8620 2.9040
Optimal strategy (deaths) [40 100 0 0] [40 100 0 0] [40 100 0 0] [21 100 0 100] [21 100 0 100] [21 100 0 100]
Illness Attack Rate (%) 1.25 5.3 10.2 24.7 32.6 33.8
Deaths (per 1000 cases) 0.4711 0.4789 0.4972 0.4711 0.5686 0.5823
doi:10.1371/journal.pone.0013767.t003
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hospitalizations. In contrast, when averting deaths, it is better to
allocate vaccine in the high-risk groups first and then cover high-
transmission groups. Once vaccine supplies reach a certain
coverage level, then it becomes important to vaccinate the high-
transmission groups in the earlier stages of the epidemic, but this
policy becomes suboptimal once the peak of the epidemic has
passed. This is because by allocating this much vaccine in children
earlier on in the epidemic, we would be able to block transmission
and mitigate the disease, but if vaccination took place later on in
the epidemic, there are too many people already infected and this
strategy is no longer optimal (see figure 3).
These results highlight several important components of
influenza epidemic control with vaccines. First, the proportion of
population that is children is extremely important. For a less
developed country, where the high-transmission group accounts for
the majority of the population, one needs large amounts of vaccine
to indirectly protect the high-risk groups by vaccinating the high-
transmission ones. However, in a developed country, where high-
risk groups represent a smaller fraction of the population, it is
possible toreduceand even mitigate transmissionby vaccinating the
high-transmission groups, if this is done early in the epidemic. The
second important point is that timingof the vaccination is extremely
important and greatly determines where the efforts should be
concentrated. Finally, while using the optimal policy greatly reduces
the size of the epidemic if done early on, all vaccination policies
perform poorly after the peak of the epidemic. It is very difficult to
identify in real time where one is in an epidemic, but it would be
evenmore difficult to switchthe vaccinationtargetgroups duringan
epidemic, both politically and logistically. Given that timing is
crucial, this suggests the necessity of better surveillance and
preparedness. In this context, our results could be used to set
Figure 6. Sensitivity analysis for adjusting influenza-related mortality and hospitalizations in a developing country setting.
Caption: Percentage of the total number of doses used in each sub-group in a less developed country when there is enough vaccine to protect 15%
of the population and the objective function was set to minimize mortality. The left panel shows the optimal values without adjusting for the excess
of deaths and hospitalizations, while in the right panel we adjusted these parameters by multiplying them by an adjusting factor (see text S1 and
table S2). The middle panel shows an intermediate adjustment: Here the adjusting factors were taken as half of the ones given in table S2 (increase in
the influenza-related mortality by a factor of 4 instead of 8 in children and 1.5 instead of 3 in adults). Adjusting these numbers tends to favor the
protection of low-risk children early in the epidemic, as opposed to protect high-risk adults.
doi:10.1371/journal.pone.0013767.g006
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population. For example, pandemic H1N1 peaked in the US in
early October 2009, and during the same period vaccination with
limited supplies of vaccine began. As a result, most vaccine was
delivered and administered well after the peak. The mass
vaccination of children that occurred had a minimal effect on
protecting others and reducing general morbidity in the population.
Despite the early accurate prediction of when the epidemic would
peak in the US [22], the vaccine arrived during the peak, for
logistical reasons, and had a limited effect.
As a first approach, we used excess in infant mortality and
excess in female adult mortality as proxies for excess in influenza-
related mortality and hospitalizations in a LDC compared with a
DC. The results were very sensitive to these parameters. This
suggests that we need studies to more accurately determine these
numbers. Hospitalizations and mortality rates in a LDC are very
different from those in a DC. People tend to not seek medical
attention unless strictly necessary due to the lack of health
insurance and the economic cost. In a pandemic situation, the
health system in a LDC is likely to quickly run out of essential
medications, to lack essential health personnel or to reach full
capacity. This will in turn increase mortality. None of these factors
were considered in our model. Furthermore, our results are
extremely sensitive to the population structure, both in the
percentages of people at high risk and in the contact pattern
among them. Here, we assumed that the contact patterns were
identical in a DC and a LDC. This is an important limitation since
the model depends strongly in this assumption. Given the
uncertainty for the parameters for pandemic H1N1 2009, we
agree with Dushoff et al. [29] that one should be cautious in
interpreting the results offered by simple models.
The model presented here is extremely simple. While we are
able to draw general conclusions, our results may not be
appropriate for specific countries. Adding more structure to the
model (for example adding more age groups, changing the
probabilities of transmission in each group, and adding other
details) will make a more realistic model for a specific situation,
and hence more realistic predictions. We assumed that the vaccine
efficacy was the same in all groups. This is a limitation since we
know that the efficacy is reduced in the elderly and takes more
time to develop in children. Finally one could expect somewhat
different results if the objective function were replaced by other
functions, such as final illness attack rates, remaining years of life
lost, economic burden or a combination of these.
Previous work [30,31,32] has suggested that in presence of low
vaccine supplies, high-risk groups should be prioritized but high-
transmission groups should be vaccinated with larger quantities of
vaccine. Our results agree with this strategy for a population with a
structure similar to the one in the US as long as vaccination starts
before the peak of the epidemic. However, we suggest that there is a
threshold in the time when a switch in the optimal strategy occurs,
after which, vaccine would be more effective if allocated directly to
the high-risk groups. This is in agreement with the results found by
others [9,33,34]. The particular time for this threshold is strongly
dependent on the values of the model parameters, in particular on
the vaccination coverage and population structure, but in general,
occurs some time during the exponential phase of the epidemic or
right at the peak. Our results suggest that if vaccination occurs too
close to the peak of the epidemic, then all the strategies considered
performed poorly, in agreement with recent work [11,12]. Our
results are novel in that we compared optimal strategies for both a
developed country and a developing country, taking into account
differences in the population structure and excess in influenza-
related mortality and hospitalizations.
Supporting Information
Figure S1 Vaccine efficacy as a function of time. Plot of the
vaccine efficacies modeled as functions of time. Once vaccine is
administered, the vaccine efficacies build up in time in an
exponentially-like fashion during the first 15 days and remain constant
afterward. The exact formula is given in Text S1.
Found at: doi:10.1371/journal.pone.0013767.s001 (0.02 MB
PDF)
Figure S2 Sensitivity analysis for the basic reproduction
number R0 for a developed country. Vaccine distribution by
group, for a developed country, with vaccine enough to cover 15%
of the population, minimizing deaths for R0=1.4, R0=1.6 and
R0=1.8 and set of respective dates considered. As R0 increases,
the optimal solution shifts the tiping point where there is a switch
from protecting low-risk children to high-risk adults.
Found at: doi:10.1371/journal.pone.0013767.s002 (0.05 MB
PDF)
Figure S3 Sensitivity analysis for adjusting influenza-
related mortality and hospitalizations in a LDC setting.
Percentage of the total number of doses used in each sub-group in a
lessdeveloped countrywhen thereis enough vaccine to protect 15%
of the population and the objective function was set to minimize
hospitalizations. The left panel shows the optimal values without
adjusting for excess of deaths and hospitalizations, while in the right
panel we adjusted these parameters by multiplying them by an
adjusting factor (see text and table S2). The middle panel illustrates
a middle-ground adjustment: The multipliers given in table S2 were
halved. (increase in the influenza-related mortality by a factor of 4
instead of 8 in children and 1.5 instead of 3 in adults).
Found at: doi:10.1371/journal.pone.0013767.s003 (0.06 MB
PDF)
Figure S4 Sensitivity analysis for adjusting influenza-
related mortality and hospitalizations in a LDC setting.
Percentage of the total number of doses used in each sub-group in
a less developed country when there is enough vaccine to protect
25% of the population and the objective function was set to
minimize mortality. The left panel shows the optimal values
without adjusting for excess of deaths and hospitalizations, while in
the right panel we adjusted these parameters by multiplying them
by an adjusting factor (see text and table S2). The middle panel
illustrates a middle-ground adjustment: the multipliers given in
table S2 were halved (increase in the influenza-related mortality by
a factor of 4 instead of 8 in children and 1.5 instead of 3 in adults).
Found at: doi:10.1371/journal.pone.0013767.s004 (0.06 MB
PDF)
Table S1 Times considered for starting vaccination for
each R0.
Found at: doi:10.1371/journal.pone.0013767.s005 (0.03 MB
PDF)
Table S2 Parameter values.
Found at: doi:10.1371/journal.pone.0013767.s006 (0.06 MB
PDF)
Table S3 Final illness attack rates for the developed
country setting for the range of basic reproduction
numbers considered.
Found at: doi:10.1371/journal.pone.0013767.s007 (0.03 MB
PDF)
Table S4 Results for a Developed Country with R0=1.4.
Found at: doi:10.1371/journal.pone.0013767.s008 (0.09 MB
PDF)
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Table S6 Results for a Less Developed Country,
influenza-related mortality and hospitalizations unad-
justed, R0=1.4.
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Table S7 Results for a Less Developed Country,
influenza-related mortality and hospitalizations adjust-
ed, R0=1.4.
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Table S8 Results for a Less Developed Country,
influenza-related mortality and hospitalizations unad-
justed, R0=1.8.
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PDF)
Table S9 Results for a Less Developed Country,
influenza-related mortality and hospitalizations adjust-
ed, R0=1.8.
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Text S1 Supplemental material for ‘Optimizing vaccine
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